{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T19:20:45Z","timestamp":1788895245327,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Hunan Science and Technology Innovation Plan","award":["2018SK2105"],"award-info":[{"award-number":["2018SK2105"]}]},{"name":"Hunan Science and Technology Innovation Plan","award":["kq1606001"],"award-info":[{"award-number":["kq1606001"]}]},{"name":"the Fundamental Research Funds for the Central Universities","award":["2019zzts019"],"award-info":[{"award-number":["2019zzts019"]}]},{"name":"the Fundamental Research Funds for the Central Universities","award":["2019zzts809"],"award-info":[{"award-number":["2019zzts809"]}]},{"name":"the Key Scientific Research and Innovation Projects of Hunan Postgraduates","award":["CX20190074"],"award-info":[{"award-number":["CX20190074"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Physiol Biochem"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s13105-020-00730-8","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T06:03:23Z","timestamp":1582610603000},"page":"279-290","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["miR-485-5p\/HSP90 axis blocks Akt1 phosphorylation to suppress osteosarcoma cell proliferation and migration via PI3K\/AKT pathway"],"prefix":"10.1007","volume":"76","author":[{"given":"Qing","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingying","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youwen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,25]]},"reference":[{"key":"730_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/00003086-197509000-00001","volume":"111","author":"WF Enneking","year":"1975","unstructured":"Enneking WF (1975) Editorial: Osteosarcoma. Clin Orthop Relat Res 111:2\u20134","journal-title":"Clin Orthop Relat Res"},{"key":"730_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/978-1-4419-0284-9_4","volume":"152","author":"AK Raymond","year":"2009","unstructured":"Raymond AK, Jaffe N (2009) Osteosarcoma multidisciplinary approach to the management from the pathologist's perspective. Cancer Treat Res 152:63\u201384","journal-title":"Cancer Treat Res"},{"issue":"2","key":"730_CR3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/BF00454247","volume":"104","author":"S Brooks","year":"1985","unstructured":"Brooks S, Starkie CM, Clarke NM (1985) Osteosarcoma after the fourth decade. A clinico-pathological review. Arch Orthop Trauma Surg 104(2):100\u2013105","journal-title":"Arch Orthop Trauma Surg"},{"issue":"3","key":"730_CR4","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/1097-0142(19910201)67:3<638::AID-CNCR2820670319>3.0.CO;2-T","volume":"67","author":"H Kozakewich","year":"1991","unstructured":"Kozakewich H, Perez-Atayde AR, Goorin AM, Wilkinson RH, Gebhardt MC, Vawter GF (1991) Osteosarcoma in young children. Cancer 67(3):638\u2013642","journal-title":"Cancer"},{"key":"730_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3389\/fonc.2014.00189","volume":"4","author":"MV Guijarro","year":"2014","unstructured":"Guijarro MV, Ghivizzani SC, Gibbs CP (2014) Animal models in osteosarcoma. Front Oncol 4:189","journal-title":"Front Oncol"},{"issue":"4","key":"730_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ctrv.2013.11.006","volume":"40","author":"A Luetke","year":"2014","unstructured":"Luetke A et al (2014) Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev 40(4):523\u2013532","journal-title":"Cancer Treat Rev"},{"key":"730_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fonc.2014.00064","volume":"4","author":"C Porta","year":"2014","unstructured":"Porta C, Paglino C, Mosca A (2014) Targeting PI3K\/Akt\/mTOR signaling in cancer. Front Oncol 4:64","journal-title":"Front Oncol"},{"key":"730_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cca.2014.12.041","volume":"444","author":"J Zhang","year":"2015","unstructured":"Zhang J et al (2015) PI3K\/Akt signaling in osteosarcoma. Clin Chim Acta 444:182\u2013192","journal-title":"Clin Chim Acta"},{"issue":"96","key":"730_CR9","first-page":"301","volume":"17","author":"W Zhou","year":"2014","unstructured":"Zhou W, Hao M, du X, Chen K, Wang G, Yang J (2014) Advances in targeted therapy for osteosarcoma. Discov Med 17(96):301\u2013307","journal-title":"Discov Med"},{"issue":"17","key":"730_CR10","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1158\/0008-5472.CAN-13-3698","volume":"74","author":"MG Rubashkin","year":"2014","unstructured":"Rubashkin MG, Cassereau L, Bainer R, DuFort C, Yui Y, Ou G, Paszek MJ, Davidson MW, Chen YY, Weaver VM (2014) Force engages vinculin and promotes tumor progression by enhancing PI3K activation of phosphatidylinositol (3,4,5)-triphosphate. Cancer Res 74(17):4597\u20134611","journal-title":"Cancer Res"},{"issue":"9","key":"730_CR11","doi-asserted-by":"publisher","first-page":"14304","DOI":"10.3390\/molecules190914304","volume":"19","author":"A Majchrzak","year":"2014","unstructured":"Majchrzak A, Witkowska M, Smolewski P (2014) Inhibition of the PI3K\/Akt\/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance. Molecules 19(9):14304\u201314315","journal-title":"Molecules"},{"issue":"5712","key":"730_CR12","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex. Science 307(5712):1098\u20131101","journal-title":"Science"},{"issue":"20","key":"730_CR13","doi-asserted-by":"publisher","first-page":"10832","DOI":"10.1073\/pnas.170276797","volume":"97","author":"S Sato","year":"2000","unstructured":"Sato S, Fujita N, Tsuruo T (2000) Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A 97(20):10832\u201310837","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"730_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s13046-018-0880-6","volume":"37","author":"X Xiao","year":"2018","unstructured":"Xiao X, Wang W, Li Y, Yang D, Li X, Shen C, Liu Y, Ke X, Guo S, Guo Z (2018) HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma. J Exp Clin Cancer Res 37(1):201","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"730_CR15","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1159\/000343336","volume":"30","author":"G Li","year":"2012","unstructured":"Li G, Cai M, Fu D, Chen K, Sun M, Cai Z, Cheng B (2012) Heat shock protein 90B1 plays an oncogenic role and is a target of microRNA-223 in human osteosarcoma. Cell Physiol Biochem 30(6):1481\u20131490","journal-title":"Cell Physiol Biochem"},{"key":"730_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1101\/sqb.2006.71.055","volume":"71","author":"AF Schier","year":"2006","unstructured":"Schier AF, Giraldez AJ (2006) MicroRNA function and mechanism: insights from zebra fish. Cold Spring Harb Symp Quant Biol 71:195\u2013203","journal-title":"Cold Spring Harb Symp Quant Biol"},{"issue":"14 Suppl","key":"730_CR17","doi-asserted-by":"publisher","first-page":"E21","DOI":"10.2527\/jas.2008-1303","volume":"87","author":"TG McDaneld","year":"2009","unstructured":"McDaneld TG (2009) MicroRNA: mechanism of gene regulation and application to livestock. J Anim Sci 87(14 Suppl):E21\u2013E28","journal-title":"J Anim Sci"},{"key":"730_CR18","doi-asserted-by":"publisher","first-page":"359739","DOI":"10.1155\/2012\/359739","volume":"2012","author":"E Kobayashi","year":"2012","unstructured":"Kobayashi E, Hornicek FJ, Duan Z (2012) MicroRNA involvement in osteosarcoma. Sarcoma 2012:359739","journal-title":"Sarcoma"},{"issue":"7","key":"730_CR19","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/0008-5472.CAN-11-2663","volume":"72","author":"KB Jones","year":"2012","unstructured":"Jones KB, Salah Z, del Mare S, Galasso M, Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, Volinia S, Stein GS, Croce CM, Lian JB, Aqeilan RI (2012) miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res 72(7):1865\u20131877","journal-title":"Cancer Res"},{"key":"730_CR20","doi-asserted-by":"publisher","first-page":"732690","DOI":"10.1155\/2011\/732690","volume":"2011","author":"RR Lulla","year":"2011","unstructured":"Lulla RR et al (2011) Identification of differentially expressed microRNAs in osteosarcoma. Sarcoma 2011:732690","journal-title":"Sarcoma"},{"issue":"4","key":"730_CR21","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1089\/cbr.2017.2394","volume":"34","author":"S He","year":"2019","unstructured":"He S, Wang Z, Tang H, Dong J, Qu Y, Lv J (2019) MiR-217 inhibits proliferation, migration, and invasion by targeting SIRT1 in osteosarcoma. Cancer Biother Radiopharm 34(4):264\u2013270","journal-title":"Cancer Biother Radiopharm"},{"key":"730_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12935-019-0829-7","volume":"19","author":"J Shi","year":"2019","unstructured":"Shi J et al (2019) miR-328-3p mediates the anti-tumor effect in osteosarcoma via directly targeting MMP-16. Cancer Cell Int 19:104","journal-title":"Cancer Cell Int"},{"issue":"1","key":"730_CR23","first-page":"883","volume":"17","author":"Q Liu","year":"2019","unstructured":"Liu Q, Geng P, Shi L, Wang Q, Wang P (2019) miR-29 promotes osteosarcoma cell proliferation and migration by targeting PTEN. Oncol Lett 17(1):883\u2013890","journal-title":"Oncol Lett"},{"issue":"3","key":"730_CR24","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.bbrc.2019.01.139","volume":"510","author":"W Liu","year":"2019","unstructured":"Liu W et al (2019) Overexpression of miR-1258 inhibits cell proliferation by targeting AKT3 in osteosarcoma. Biochem Biophys Res Commun 510(3):479\u2013486","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"730_CR25","first-page":"1664","volume":"17","author":"X Chen","year":"2019","unstructured":"Chen X, Lv C, Zhu X, Lin W, Wang L, Huang Z, Yang S, Sun J (2019) MicroRNA-504 modulates osteosarcoma cell chemoresistance to cisplatin by targeting p53. Oncol Lett 17(2):1664\u20131674","journal-title":"Oncol Lett"},{"key":"730_CR26","doi-asserted-by":"crossref","unstructured":"Cavanagh BL et al Thymidine analogues for tracking DNA synthesis. Molecules 16(12):7980\u20137993","DOI":"10.3390\/molecules16097980"},{"issue":"4","key":"730_CR27","first-page":"1418","volume":"23","author":"ZB Liu","year":"2019","unstructured":"Liu ZB, Wang JA, Lv RQ (2019) Downregulation of long non-coding RNA DBH-AS1 inhibits osteosarcoma progression by PI3K-AKT signaling pathways and indicates good prognosis. Eur Rev Med Pharmacol Sci 23(4):1418\u20131427","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"730_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-016-0373-z","volume":"10","author":"P Angulo","year":"2017","unstructured":"Angulo P, Kaushik G, Subramaniam D, Dandawate P, Neville K, Chastain K, Anant S (2017) Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy. J Hematol Oncol 10(1):10","journal-title":"J Hematol Oncol"},{"issue":"7","key":"730_CR29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489\u2013501","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"730_CR30","doi-asserted-by":"publisher","first-page":"6194","DOI":"10.1158\/0008-5472.CAN-13-0518","volume":"73","author":"YP Liu","year":"2013","unstructured":"Liu YP, Liao WC, Ger LP, Chen JC, Hsu TI, Lee YC, Chang HT, Chen YC, Jan YH, Lee KH, Zeng YH, Hsiao M, Lu PJ (2013) Carboxyl-terminal modulator protein positively regulates Akt phosphorylation and acts as an oncogenic driver in breast cancer. Cancer Res 73(20):6194\u20136205","journal-title":"Cancer Res"},{"issue":"6","key":"730_CR31","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1007\/s10637-018-0624-7","volume":"36","author":"C Wang","year":"2018","unstructured":"Wang C, Jing J, Cheng L (2018) Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma. Investig New Drugs 36(6):1116\u20131132","journal-title":"Investig New Drugs"},{"issue":"4","key":"730_CR32","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s13277-013-0940-7","volume":"34","author":"J Miao","year":"2013","unstructured":"Miao J, Wu S, Peng Z, Tania M, Zhang C (2013) MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects. Tumour Biol 34(4):2093\u20132098","journal-title":"Tumour Biol"},{"key":"730_CR33","doi-asserted-by":"publisher","first-page":"788","DOI":"10.2741\/4163","volume":"18","author":"W Liang","year":"2013","unstructured":"Liang W et al (2013) The miRNAs in the pathgenesis of osteosarcoma. Front Biosci (Landmark Ed) 18:788\u2013794","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"1","key":"730_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0300060513475959","volume":"41","author":"G Zhou","year":"2013","unstructured":"Zhou G, Shi X, Zhang J, Wu S, Zhao J (2013) MicroRNAs in osteosarcoma: from biological players to clinical contributors, a review. J Int Med Res 41(1):1\u201312","journal-title":"J Int Med Res"},{"issue":"2","key":"730_CR35","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s12253-010-9307-1","volume":"17","author":"X Chen","year":"2011","unstructured":"Chen X et al (2011) Activation of the PI3K\/Akt pathway mediates bone morphogenetic protein 2-induced invasion of pancreatic cancer cells Panc-1. Pathol Oncol Res 17(2):257\u2013261","journal-title":"Pathol Oncol Res"},{"issue":"6","key":"730_CR36","first-page":"6463","volume":"14","author":"Y Gan","year":"2017","unstructured":"Gan Y, He L, Yao K, Tan J, Zeng Q, Dai Y, Liu J, Tang Y (2017) Knockdown of HMGN5 increases the chemosensitivity of human urothelial bladder cancer cells to cisplatin by targeting PI3K\/Akt signaling. Oncol Lett 14(6):6463\u20136470","journal-title":"Oncol Lett"},{"issue":"1","key":"730_CR37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1615\/CritRevOncog.v17.i1.60","volume":"17","author":"K Sheppard","year":"2012","unstructured":"Sheppard K, Kinross KM, Solomon B, Pearson RB, Phillips WA (2012) Targeting PI3 kinase\/AKT\/mTOR signaling in cancer. Crit Rev Oncog 17(1):69\u201395","journal-title":"Crit Rev Oncog"},{"issue":"3","key":"730_CR38","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3892\/ol.2014.2293","volume":"8","author":"S Shi","year":"2014","unstructured":"Shi S, Cao H (2014) Shikonin promotes autophagy in BXPC-3 human pancreatic cancer cells through the PI3K\/Akt signaling pathway. Oncol Lett 8(3):1087\u20131089","journal-title":"Oncol Lett"},{"issue":"3","key":"730_CR39","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/bab.1193","volume":"62","author":"ZM Xiao","year":"2015","unstructured":"Xiao ZM, Wang XY, Wang AM (2015) Periostin induces chemoresistance in colon cancer cells through activation of the PI3K\/Akt\/survivin pathway. Biotechnol Appl Biochem 62(3):401\u2013406","journal-title":"Biotechnol Appl Biochem"},{"issue":"7","key":"730_CR40","first-page":"3984","volume":"7","author":"LB Zhu","year":"2014","unstructured":"Zhu LB, Jiang J, Zhu XP, Wang TF, Chen XY, Luo QF, Shu Y, Liu ZL, Huang SH (2014) Knockdown of Aurora-B inhibits osteosarcoma cell invasion and migration via modulating PI3K\/Akt\/NF-kappaB signaling pathway. Int J Clin Exp Pathol 7(7):3984\u20133991","journal-title":"Int J Clin Exp Pathol"},{"issue":"22","key":"730_CR41","doi-asserted-by":"publisher","first-page":"13375","DOI":"10.1074\/jbc.273.22.13375","volume":"273","author":"T Maehama","year":"1998","unstructured":"Maehama T, Dixon JE (1998) The tumor suppressor, PTEN\/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273(22):13375\u201313378","journal-title":"J Biol Chem"},{"issue":"1","key":"730_CR42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cell.2007.06.034","volume":"130","author":"M Mumby","year":"2007","unstructured":"Mumby M (2007) PP2A: unveiling a reluctant tumor suppressor. Cell 130(1):21\u201324","journal-title":"Cell"},{"issue":"1","key":"730_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.molcel.2005.03.008","volume":"18","author":"T Gao","year":"2005","unstructured":"Gao T, Furnari F, Newton AC (2005) PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18(1):13\u201324","journal-title":"Mol Cell"},{"issue":"6","key":"730_CR44","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.3892\/etm.2017.4360","volume":"13","author":"J Zhu","year":"2017","unstructured":"Zhu J, Liu Y, Zhu Y, Zeng M, Xie J, Lei P, Li K, Hu Y (2017) Role of RANK and Akt1 activation in human osteosarcoma progression: a clinicopathological study. Exp Ther Med 13(6):2862\u20132866","journal-title":"Exp Ther Med"},{"key":"730_CR45","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.canlet.2018.04.027","volume":"428","author":"Q Zou","year":"2018","unstructured":"Zou Q et al (2018) miR-19a-mediated downregulation of RhoB inhibits the dephosphorylation of AKT1 and induces osteosarcoma cell metastasis. Cancer Lett 428:147\u2013159","journal-title":"Cancer Lett"},{"issue":"7","key":"730_CR46","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/01.cad.0000136876.11928.be","volume":"15","author":"J Beliakoff","year":"2004","unstructured":"Beliakoff J, Whitesell L (2004) Hsp90: an emerging target for breast cancer therapy. Anti-Cancer Drugs 15(7):651\u2013662","journal-title":"Anti-Cancer Drugs"},{"issue":"5","key":"730_CR47","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0093-7754(03)00346-4","volume":"30","author":"DB Solit","year":"2003","unstructured":"Solit DB, Scher HI, Rosen N (2003) Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 30(5):709\u2013716","journal-title":"Semin Oncol"},{"issue":"2","key":"730_CR48","first-page":"211","volume":"1835","author":"MM Centenera","year":"2013","unstructured":"Centenera MM et al (2013) Hsp90: still a viable target in prostate cancer. Biochim Biophys Acta 1835(2):211\u2013218","journal-title":"Biochim Biophys Acta"},{"key":"730_CR49","first-page":"11","volume":"7","author":"K Esfahani","year":"2016","unstructured":"Esfahani K, Cohen V (2016) HSP90 as a novel molecular target in non-small-cell lung cancer. Lung Cancer (Auckl) 7:11\u201317","journal-title":"Lung Cancer (Auckl)"},{"issue":"2","key":"730_CR50","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.bbcan.2019.01.002","volume":"1871","author":"K Kryeziu","year":"2019","unstructured":"Kryeziu K, Bruun J, Guren TK, Sveen A, Lothe RA (2019) Combination therapies with HSP90 inhibitors against colorectal cancer. Biochim Biophys Acta Rev Cancer 1871(2):240\u2013247","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"730_CR51","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/jcb.26260","volume":"119","author":"GH Liang","year":"2018","unstructured":"Liang GH, Liu N, He MT, Yang J, Liang ZJ, Gao XJ, Rahhal AH, He QY, Zhang HT, Zha ZG (2018) Transcriptional regulation of Runx2 by HSP90 controls osteosarcoma apoptosis via the AKT\/GSK-3beta\/beta-catenin signaling. J Cell Biochem 119(1):948\u2013959","journal-title":"J Cell Biochem"},{"issue":"12","key":"730_CR52","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1002\/ijc.24660","volume":"125","author":"JK McCleese","year":"2009","unstructured":"McCleese JK et al (2009) The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. Int J Cancer 125(12):2792\u20132801","journal-title":"Int J Cancer"},{"issue":"8","key":"730_CR53","first-page":"2315","volume":"22","author":"TD He","year":"2018","unstructured":"He TD, Zhu JK, Wei ZX, Wang YM (2018) MicroRNA-520d-3p inhibits osteosarcoma progression by degradation of Akt1. Eur Rev Med Pharmacol Sci 22(8):2315\u20132320","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"11","key":"730_CR54","doi-asserted-by":"publisher","first-page":"8579","DOI":"10.1007\/s13277-015-3614-9","volume":"36","author":"ZC Shi","year":"2015","unstructured":"Shi ZC et al (2015) MicroRNA-375 functions as a tumor suppressor in osteosarcoma by targeting PIK3CA. Tumour Biol 36(11):8579\u20138584","journal-title":"Tumour Biol"},{"issue":"5","key":"730_CR55","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.prp.2018.03.013","volume":"214","author":"ZJ Gao","year":"2018","unstructured":"Gao ZJ et al (2018) miR-486-5p functions as an oncogene by targeting PTEN in non-small cell lung cancer. Pathol Res Pract 214(5):700\u2013705","journal-title":"Pathol Res Pract"},{"key":"730_CR56","doi-asserted-by":"crossref","unstructured":"Jin X et al (2019) MicroRNA-486-5p improves nonsmall-cell lung cancer chemotherapy sensitivity and inhibits epithelial-mesenchymal transition by targeting twinfilin actin binding protein 1. J Int Med Res:300060519850739","DOI":"10.1177\/0300060519850739"}],"container-title":["Journal of Physiology and Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13105-020-00730-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13105-020-00730-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13105-020-00730-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:31:42Z","timestamp":1614126702000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13105-020-00730-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,25]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["730"],"URL":"https:\/\/doi.org\/10.1007\/s13105-020-00730-8","relation":{},"ISSN":["1138-7548","1877-8755"],"issn-type":[{"value":"1138-7548","type":"print"},{"value":"1877-8755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,25]]},"assertion":[{"value":"28 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Second Xiangya Hospital and with the 1964 Helsinki declaration. Informed consent to participate in the study has been obtained from participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Consent for publication was obtained from the participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}